Kyoung-Ha Park1, Taek-Geun Kwon2, Yasushi Matsuzawa2, Tao Sun2, Zhi Liu2, Ryan J Lennon3, Lilach O Lerman4, Sudhir S Kushwaha2, Amir Lerman5. 1. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA Division of Cardiovascular Disease, Hallym University Medical Center, Anyang, Korea. 2. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. 3. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA. 4. Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. 5. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA lerman.amir@mayo.edu.
Abstract
AIMS: The current study was designed to test that vasa vasorum (VV) plays a role in the progression of cardiac allograft vasculopathy (CAV) in patients with heart transplantation (HTX). METHODS AND RESULTS: Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) were performed in the left anterior descending artery in 19 segments of 19 HTX patients (median 2.1 years from HTX). Each segment is composed of both the continuous lesions: (i) CAV area: intimal thickness >0.5 mm with 5 mm length and (ii) VV area: intimal thickness ≤0.5 mm with 5 mm length. The per cent VV volume (VV volume/vessel volume × 100, %VV) was evaluated in the VV area with OCT (in CAV area VV cannot be assessed because of limited penetration power of OCT). A year later, the association between the baseline %VV and the change in per cent plaque volume (plaque volume/vessel volume × 100, %PV) was evaluated with IVUS. To a normal distribution, Δ%PV (follow-up %PV-initial %PV) was undergone square root transformation. The correlations between the %VV at baseline study and square root-Δ%PV were significant both in the CAV area and in the VV area (r = 0.787, P < 0.001 and r = 0.701, P < 0.001, respectively). In multivariable analysis, only the %VV was significantly correlated with square root-Δ%PV in both areas. CONCLUSION: The current study demonstrated a significant association between the VV volume and the progression of plaque volume in both the CAV area and the VV area. Thus, VV may be a potential predictor and possible therapeutic target to attenuate CAV. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The current study was designed to test that vasa vasorum (VV) plays a role in the progression of cardiac allograft vasculopathy (CAV) in patients with heart transplantation (HTX). METHODS AND RESULTS: Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) were performed in the left anterior descending artery in 19 segments of 19 HTX patients (median 2.1 years from HTX). Each segment is composed of both the continuous lesions: (i) CAV area: intimal thickness >0.5 mm with 5 mm length and (ii) VV area: intimal thickness ≤0.5 mm with 5 mm length. The per cent VV volume (VV volume/vessel volume × 100, %VV) was evaluated in the VV area with OCT (in CAV area VV cannot be assessed because of limited penetration power of OCT). A year later, the association between the baseline %VV and the change in per cent plaque volume (plaque volume/vessel volume × 100, %PV) was evaluated with IVUS. To a normal distribution, Δ%PV (follow-up %PV-initial %PV) was undergone square root transformation. The correlations between the %VV at baseline study and square root-Δ%PV were significant both in the CAV area and in the VV area (r = 0.787, P < 0.001 and r = 0.701, P < 0.001, respectively). In multivariable analysis, only the %VV was significantly correlated with square root-Δ%PV in both areas. CONCLUSION: The current study demonstrated a significant association between the VV volume and the progression of plaque volume in both the CAV area and the VV area. Thus, VV may be a potential predictor and possible therapeutic target to attenuate CAV. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: G S Mintz; S E Nissen; W D Anderson; S R Bailey; R Erbel; P J Fitzgerald; F J Pinto; K Rosenfield; R J Siegel; E M Tuzcu; P G Yock Journal: J Am Coll Cardiol Date: 2001-04 Impact factor: 24.094
Authors: Stephanie H Wilson; Joerg Herrmann; Lilach O Lerman; David R Holmes; Claudio Napoli; Erik L Ritman; Amir Lerman Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: Jon A Kobashigawa; Jonathan M Tobis; Randall C Starling; E Murat Tuzcu; Andrew L Smith; Hannah A Valantine; Alan C Yeung; Mandeep R Mehra; Hitoshi Anzai; Brandy T Oeser; Kamal H Abeywickrama; Jane Murphy; Nathalie Cretin Journal: J Am Coll Cardiol Date: 2005-05-03 Impact factor: 24.094
Authors: H Tsutsui; K M Ziada; P Schoenhagen; A Iyisoy; W A Magyar; T D Crowe; J D Klingensmith; D G Vince; G Rincon; R E Hobbs; M Yamagishi; S E Nissen; E M Tuzcu Journal: Circulation Date: 2001-08-07 Impact factor: 29.690
Authors: H M Kwon; G Sangiorgi; E L Ritman; C McKenna; D R Holmes; R S Schwartz; A Lerman Journal: J Clin Invest Date: 1998-04-15 Impact factor: 14.808
Authors: P R Rickenbacher; F J Pinto; A Chenzbraun; J Botas; N P Lewis; E L Alderman; H A Valantine; S A Hunt; J S Schroeder; R L Popp Journal: J Am Coll Cardiol Date: 1995-01 Impact factor: 24.094
Authors: Tatsuo Aoki; Martin Rodriguez-Porcel; Yoshiki Matsuo; Andrew Cassar; Teak-Geun Kwon; Federico Franchi; Rajiv Gulati; Sudhir S Kushwaha; Ryan J Lennon; Lilach O Lerman; Erik L Ritman; Amir Lerman Journal: Atherosclerosis Date: 2015-01-20 Impact factor: 5.162
Authors: Ahmad F Hedayat; Kyoung-Ha Park; Taek-Geun Kwon; John R Woollard; Kai Jiang; Daniel F Carlson; Amir Lerman; Lilach O Lerman Journal: Transl Res Date: 2017-11-03 Impact factor: 7.012
Authors: Fang Yuan; Liang Guo; Kyoung-Ha Park; John R Woollard; Kwon Taek-Geun; Kai Jiang; Tamene Melkamu; Bin Zang; Samantha L Smith; Scott C Fahrenkrug; Frank D Kolodgie; Amir Lerman; Renu Virmani; Lilach O Lerman; Daniel F Carlson Journal: J Am Heart Assoc Date: 2018-03-23 Impact factor: 5.501